Hospital Virgen de la Victoria
Hospital Virgen de la Victoria
Málaga, Spain8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients | Acute Myeloid Leukemia With Gene Mutations | Recruiting | Phase 2 | 2026-09-22 | NCT07507760 | |
| Is the 3D-PANC MSP Model Superior to CT for Assessing Response to Neoadjuvant Treatment in PCA Patients? | pancreatic adenocarcinoma | Recruiting | Not stated | 2026-09-11 | NCT06582342 | |
| Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | Breast Cancer Recurrent | Active, not recruiting | Phase 3 | 2026-09-03 | NCT03820830 | |
| TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 2 | 2026-06-17 | NCT03833479 | |
| Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | human papillomavirus-related penile squamous cell carcinoma, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-02-05 | NCT03260023 | |
| HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a) | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm | Active, not recruiting | Not applicable | 2025-09-09 | NCT04257162 | |
| Usefulness of PET-CT for Invasive Fungal Infection | Bacterial Infections and Mycoses, Infections, Invasive Fungal Infections, fungal infectious disease | Recruiting | Not stated | 2024-11-06 | NCT05688592 | |
| Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | Newly Diagnosed Multiple Myeloma | Active, not recruiting | Phase 3 | 2022-09-14 | NCT03742297 |